Tectochrysin alleviates idiopathic pulmonary fibrosis via inhibiting PI3K/AKT/mTOR signaling pathway by targeting PI3K p85
Pulmonary Pharmacology & Therapeutics · 2026-12 · 95 · 102455
DOI: 10.1016/j.pupt.2026.102455 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pulmonary Pharmacology & Therapeutics, 2026-12. Verfasst von Mengying Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Yueqing Hospital, Wenzhou Medical University, Wenzhou, 325600, Zhejiang, China; Chemical Biology Research Center, School of Pharmaceutical…. Die Arbeit nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
OBJECTIVE: Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by progressive dyspnea, with high morbidity and mortality globally. Tectochrysin, a flavonoid with several pharmacological activities, has not yet been explored for its anti-fibrotic effects. This study aims to investigate the role of tectochrysin in bleomycin (BLM)-induced IPF in mice, as well as its mechanism and target. METHODS: Intratracheal injection of BLM was employed to induce IPF in mice, and the protective effect of tectochrysin was evaluated through multiple experimental techniques. In vitro, TGF-β1-stimulated human embryonic lung fibroblasts (HELFs) was used to assess the anti-fibrotic activity of tectochrysin. Network pharmacology, bioinformatics, molecular docking, cellular thermal shift assay and drug affinity responsive target stability experiments were employed to explore the anti-fibrotic targets and mechanisms. RESULTS: In vivo, tectochrysin effectively mitigated BLM-induced extracellular matrix deposition, reduced the expression of fibrosis-related factors, and ameliorated lung injury. In vitro, tectochrysin dose-dependently inhibited TGF-β-induced α-SMA and collagen 1 expression, as well as the migration of HELFs. Notably, the inhibitory effect of tectochrysin on HELF activation and migration reached a level comparable to that of the positive control, pirfenidone, in this in vitro system. Further investigations revealed that tectochrysin directly bind to PI3K p85, forming hydrogen bonds with THR-369 and LYS-382 residues, thereby inhibiting the activation of the PI3K/AKT/mTOR signaling pathway. CONCLUSION: Tectochrysin can alleviate BLM-induced IPF by targeting PI3K p85, thereby inhibiting the activation of the PI3K/AKT/mTOR signaling pathway. This study uncovers a previously unreported anti-fibrotic activity of tectochrysin, and highlight its potential as a candidate for the treatment of IPF.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Affiliated Yueqing Hospital, Wenzhou Medical University, Wenzhou, 325600, Zhejiang, China; Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, Chin…
- Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
- Affiliated Yueqing Hospital, Wenzhou Medical University, Wenzhou, 325600, Zhejiang, China. Electronic address: 89418521@qq.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, M., Xiao, T., Chen, X., Liu, Z., Ji, H., Chen, H., Xi, X., Zhang, Y., & Zhu, X. (2026). Tectochrysin alleviates idiopathic pulmonary fibrosis via inhibiting PI3K/AKT/mTOR signaling pathway by targeting PI3K p85. Pulmonary Pharmacology & Therapeutics, 95, 102455. https://doi.org/10.1016/j.pupt.2026.102455
Vancouver
Li M, Xiao T, Chen X, Liu Z, Ji H, Chen H, et al. Tectochrysin alleviates idiopathic pulmonary fibrosis via inhibiting PI3K/AKT/mTOR signaling pathway by targeting PI3K p85. Pulmonary Pharmacology & Therapeutics. 2026;95:102455. doi:10.1016/j.pupt.2026.102455
BibTeX
@article{Li2026,
author = {Li, Mengying and Xiao, Tingfang and Chen, Xuanyu and Liu, Zhihe and Ji, Haoyu and Chen, Huiwen and Xi, Xinru and Zhang, Yali and Zhu, Xiaona},
title = {Tectochrysin alleviates idiopathic pulmonary fibrosis via inhibiting PI3K/AKT/mTOR signaling pathway by targeting PI3K p85},
journal = {Pulmonary Pharmacology & Therapeutics},
year = {2026},
volume = {95},
pages = {102455},
doi = {10.1016/j.pupt.2026.102455}
}
EUVIMED